Is CBD capable of everything it has been advertised to do? See this NY Times report.
CBD it seems is everywhere. You can find it being sold through multi level marketing, through doctors offices, and even through the local bodega.
This past weekend I was at a conference for NJ Chiropractors in New Brunswick and asked one vendor many of the hard questions. One of the questions had to do with GW pharmaceutical’s who sells a manufactured CBD, as opposed to a naturally grown version of the hemp plant. Apparently, not all the CBD plants are the same and neither is the CBD that is extracted from it. According to this one vendor, theirs is from a natural source and uses no pesticides. Apparently, many of the other vendors said similar things.
CBD can be dosed sub lingual (under the tongue) for about a minute and the dosage that works for one person may need to be adjusted for another. Others have the oil in a cream or other topical.
Apparently, depending on the type of CBD that is in the preparation and the plant being harvested, it works on the same pain receptors as opioids but it is non addictive.
I then attended a nutrition class that further explained the pathways CBD worked on and it may be a great substitute for methadone, often used to help wean patients off opioid usage. It is merely a substance that helps with pain pathways, is a great anti oxidant and can be a mild blood thinner too.
I wish to share this recent article featured in the NY Times which also looks into CBD. Check it out below
Can CBD Really Do All That?
How one molecule from the cannabis plant
came to be seen as a therapeutic cure-all.
By MOISES VELASQUEZ-MANOFF MAY 14, 2019
When Catherine Jacobson first heard about the promise of cannabis, she was at wits’ end. Her 3-year-old son, Ben, had suffered from epileptic seizures since he was 3 months old, a result of a brain malformation called polymicrogyria. Over the years, Jacobson and her husband, Aaron, have tried giving him at least 16 different drugs, but none provided lasting relief. They lived with the grim prognosis that their son — whose cognitive abilities never advanced beyond those of a 1-year-old — would likely continue to endure seizures until the cumulative brain injuries led to his death.
In early 2012, when Jacobson learned about cannabis at a conference organized by the Epilepsy Therapy Project, she felt a flicker of hope. The meeting, in downtown San Francisco, was unlike others she had attended, which were usually geared toward lab scientists and not directly focused on helping patients. This gathering aimed to get new treatments into patients’ hands as quickly as possible. Attendees weren’t just scientists and people from the pharmaceutical industry. They also included, on one day of the event, families of patients with epilepsy.